Literature DB >> 17322884

Duplication of Atxn1l suppresses SCA1 neuropathology by decreasing incorporation of polyglutamine-expanded ataxin-1 into native complexes.

Aaron B Bowman1, Yung C Lam, Paymaan Jafar-Nejad, Hung-Kai Chen, Ronald Richman, Rodney C Samaco, John D Fryer, Juliette J Kahle, Harry T Orr, Huda Y Zoghbi.   

Abstract

Spinocerebellar ataxia type 1 (SCA1) is a dominantly inherited neurodegenerative disease caused by expansion of a glutamine tract in ataxin-1 (ATXN1). SCA1 pathogenesis studies support a model in which the expanded glutamine tract causes toxicity by modulating the normal activities of ATXN1. To explore native interactions that modify the toxicity of ATXN1, we generated a targeted duplication of the mouse ataxin-1-like (Atxn1l, also known as Boat) locus, a highly conserved paralog of SCA1, and tested the role of this protein in SCA1 pathology. Using a knock-in mouse model of SCA1 that recapitulates the selective neurodegeneration seen in affected individuals, we found that elevated Atxn1l levels suppress neuropathology by displacing mutant Atxn1 from its native complex with Capicua (CIC). Our results provide genetic evidence that the selective neuropathology of SCA1 arises from modulation of a core functional activity of ATXN1, and they underscore the importance of studying the paralogs of genes mutated in neurodegenerative diseases to gain insight into mechanisms of pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17322884     DOI: 10.1038/ng1977

Source DB:  PubMed          Journal:  Nat Genet        ISSN: 1061-4036            Impact factor:   38.330


  42 in total

Review 1.  Genetically engineered mouse models of the trinucleotide-repeat spinocerebellar ataxias.

Authors:  Melissa A C Ingram; Harry T Orr; H Brent Clark
Journal:  Brain Res Bull       Date:  2011-07-23       Impact factor: 4.077

2.  Disease-toxicant screen reveals a neuroprotective interaction between Huntington's disease and manganese exposure.

Authors:  B Blairanne Williams; Daphne Li; Michal Wegrzynowicz; Bhavin K Vadodaria; Joel G Anderson; Gunnar F Kwakye; Michael Aschner; Keith M Erikson; Aaron B Bowman
Journal:  J Neurochem       Date:  2009-10-21       Impact factor: 5.372

Review 3.  Beyond the glutamine expansion: influence of posttranslational modifications of ataxin-1 in the pathogenesis of spinocerebellar ataxia type 1.

Authors:  Hyoungseok Ju; Hiroshi Kokubu; Janghoo Lim
Journal:  Mol Neurobiol       Date:  2014-04-22       Impact factor: 5.590

4.  Broad therapeutic benefit after RNAi expression vector delivery to deep cerebellar nuclei: implications for spinocerebellar ataxia type 1 therapy.

Authors:  Megan S Keiser; Ryan L Boudreau; Beverly L Davidson
Journal:  Mol Ther       Date:  2013-12-12       Impact factor: 11.454

Review 5.  Huntington's Disease.

Authors:  Steven Finkbeiner
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-06-01       Impact factor: 10.005

Review 6.  Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1.

Authors:  Huda Y Zoghbi; Harry T Orr
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

7.  RNAi or overexpression: alternative therapies for Spinocerebellar Ataxia Type 1.

Authors:  Megan S Keiser; James C Geoghegan; Ryan L Boudreau; Kim A Lennox; Beverly L Davidson
Journal:  Neurobiol Dis       Date:  2013-04-10       Impact factor: 5.996

8.  Broad distribution of ataxin 1 silencing in rhesus cerebella for spinocerebellar ataxia type 1 therapy.

Authors:  Megan S Keiser; Jeffrey H Kordower; Pedro Gonzalez-Alegre; Beverly L Davidson
Journal:  Brain       Date:  2015-10-21       Impact factor: 13.501

9.  Partial loss of ataxin-1 function contributes to transcriptional dysregulation in spinocerebellar ataxia type 1 pathogenesis.

Authors:  Juan Crespo-Barreto; John D Fryer; Chad A Shaw; Harry T Orr; Huda Y Zoghbi
Journal:  PLoS Genet       Date:  2010-07-08       Impact factor: 5.917

10.  Polyglutamine disease toxicity is regulated by Nemo-like kinase in spinocerebellar ataxia type 1.

Authors:  Hyoungseok Ju; Hiroshi Kokubu; Tiffany W Todd; Juliette J Kahle; Soeun Kim; Ronald Richman; Karthik Chirala; Harry T Orr; Huda Y Zoghbi; Janghoo Lim
Journal:  J Neurosci       Date:  2013-05-29       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.